Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/179214
Title: Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018)
Author: Cantón, Rafael
Loza, Elena
Arcay, Ricardo M.
Cercenado, Emilia
Castillo, Francisco Javier
Cisterna, Ramón
Gálvez Benítez, Lidia
González Romo, Fernando
Hernández Cabezas, Alicia
Rodríguez Lozano, Jesús
Suárez Barrenechea, Ana Isabel
Tubau, Fe
Díaz Regañón, Jazmín
López Mendoza, Diego
SMART-Spain Working Group
Keywords: Pseudomonas
Resistència als medicaments
Medicaments antibacterians
Epidemiologia
Pseudomonas
Drug resistance
Antibacterial agents
Epidemiology
Issue Date: 1-Mar-2021
Publisher: Sociedad Española de Quimioterapia
Abstract: Objective: To analyse the susceptibility to ceftolozane-tazobactam and comparators in Enterobacterales and Pseudomonas aeruginosa isolates recovered from intraabdominal (IAI), urinary (UTI), respiratory (RTI) and bloodstream infection (BSI) in the SMART (Study for Monitoring Antimicrobial Resistance Trends) study. Methods: The susceptibility of 5,351 isolates collected in 11 Spanish hospitals (2016-2018) were analysed (EUCAST-2020 criteria) by broth microdilution and were phenotypically studied for the presence of extended-spectrum beta-lactamases (ESBL). Ceftolozane-tazobactam and/or carbapenem resistant isolates were genetically characterized for ESBL and carbapenemases. Results: Escherichia coli was the most frequent pathogen (49.3% IAI, 54.9% UTI, 16.7% RTI and 50% BSI), followed by Klebsiella pneumoniae (11.9%, 19.1%, 13.1% and 15.4%, respectively). P. aeruginosa was isolated in 9.3%, 5.6%, 32% and 9%, respectively. The frequency of isolates with ESBLs (2016-2017) was: 30.5% K. pneumoniae, 8.6% E. coli, 2.3% Klebsiella oxytoca and 0.7% Proteus mirabilis. Ceftolozane-tazobactam was very active against non-ESBL-(99.3% susceptible) and ESBL-(95.2%) producing E. coli being less active against K. pneumoniae (98% and 43.1%, respectively) isolates. CTX-M-15 was the most prevalent ESBL in E. coli (27.5%) and K. pneumoniae (51.9%) frequently associated with OXA-48-like carbapenemase. Overall, 93% of P. aeruginosa isolates were susceptible to ceftolozane-tazobactam, preserving this activity (>75%) in isolates resistant to other beta-lactams except in those resistant to meropenen or ceftazidime-avibactam. GES-5, PER-1, VIM-1/2 were the most prevalent enzymes in isolates resistant to ceftolozane-tazobactam. Conclusions: Ceftolozane-tazobactam showed high activity rates against isolates recovered in the SMART study although it was affected in K. pneumoniae and P. aeruginosa isolates with ESBL and/or carbapenemases.
Note: Reproducció del document publicat a: https://doi.org/10.37201/req/019.2021
It is part of: Revista Española de Quimioterapia, 2021, vol. 34, num. 3, p. 228-237
URI: http://hdl.handle.net/2445/179214
Related resource: https://doi.org/10.37201/req/019.2021
ISSN: 0214-3429
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
canton01mar2021.pdf493.5 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons